FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175110217> ?p ?o ?g. }

• W3175110217 abstract "Objective: To investigate the efficacy of galcanezumab in episodic migraine (EM) by subgroups of low-versus high-frequency of migraine headaches. Background: Migraine is a neurological disorder with high disease burden and unmet clinical need. Design/Methods: Data were pooled from two phase 3 randomized trials. Headaches were tracked via an electronic patient-reported outcome system, and randomization was stratified by low-frequency (LFEM; 4–7 monthly migraine headache days [MHD]) or high-frequency (HFEM; 8–14 monthly MHD). Subgroup analysis of efficacy data, including functional impact and disability measures, were conducted for LFEM and HFEM subgroups with a linear or generalized linear mixed model repeated measures approach. Results: For intent-to-treat patients (N=1773), mean age was 41.3 years, majority were white (75%), female (85%), and HFEM was present in 66% of patients. There were no statistically significant (p Conclusions: Overall, treatment effects of both doses of galcanezumab were similar with regard to reduction in monthly MHD, improved functioning, and reduced disability for both LFEM and HFEM subgroups. The percentage of patients with ≥50%, ≥75%, and 100% reduction from baseline in MHDs were similar between LFEM and HFEM subgroups. Disclosure: Dr. Silberstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder Biopharmaceuticals, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Labrys Biologics, Medscape, Medtronic, Neuralieve, NINDS, Pfizer, and Teva. Dr. Silberstein has received compensation for serving on the Board of Directors of eNeura and Biohaven. Dr. Silberstein has received royalty, license fees, or contractual rights payments from Biohaven. Dr. Silberstein holds stock and/or stock options in Biohaven which sponsored research in which Dr. Silberstein was involved as an investigator. Dr. Silberstein holds stock and/or stock options in Biohaven. Dr. Silberstein has received research support from Allergan, Amgen, Cumberland Pharmaceuticals, ElectroCore Medical, Labrys Biologics, Eli Lilly, Merz, and Troy Healthcare.. Dr. Stauffer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Lipsius has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Syneos Health. Dr. Wilson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, electroCore Medical, Lilly USA, and Teva Pharmaceuticals." @default.
• W3175110217 created "2021-07-05" @default.
• W3175110217 creator A5012477547 @default.
• W3175110217 creator A5015085334 @default.
• W3175110217 creator A5023730853 @default.
• W3175110217 creator A5061864796 @default.
• W3175110217 creator A5067239965 @default.
• W3175110217 date "2019-04-09" @default.
• W3175110217 modified "2023-09-24" @default.
• W3175110217 title "Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Subgroup Analyses of Efficacy by Low-Versus High-Frequency of Migraine Headaches (S17.003)" @default.
• W3175110217 hasPublicationYear "2019" @default.
• W3175110217 type Work @default.
• W3175110217 sameAs 3175110217 @default.
• W3175110217 citedByCount "0" @default.
• W3175110217 crossrefType "journal-article" @default.
• W3175110217 hasAuthorship W3175110217A5012477547 @default.
• W3175110217 hasAuthorship W3175110217A5015085334 @default.
• W3175110217 hasAuthorship W3175110217A5023730853 @default.
• W3175110217 hasAuthorship W3175110217A5061864796 @default.
• W3175110217 hasAuthorship W3175110217A5067239965 @default.
• W3175110217 hasConcept C102959455 @default.
• W3175110217 hasConcept C105795698 @default.
• W3175110217 hasConcept C118552586 @default.
• W3175110217 hasConcept C126322002 @default.
• W3175110217 hasConcept C1862650 @default.
• W3175110217 hasConcept C187960798 @default.
• W3175110217 hasConcept C2777106319 @default.
• W3175110217 hasConcept C2777683783 @default.
• W3175110217 hasConcept C2778186239 @default.
• W3175110217 hasConcept C2778541695 @default.
• W3175110217 hasConcept C2780966972 @default.
• W3175110217 hasConcept C2910587157 @default.
• W3175110217 hasConcept C33923547 @default.
• W3175110217 hasConcept C512399662 @default.
• W3175110217 hasConcept C535046627 @default.
• W3175110217 hasConcept C71924100 @default.
• W3175110217 hasConcept C95190672 @default.
• W3175110217 hasConceptScore W3175110217C102959455 @default.
• W3175110217 hasConceptScore W3175110217C105795698 @default.
• W3175110217 hasConceptScore W3175110217C118552586 @default.
• W3175110217 hasConceptScore W3175110217C126322002 @default.
• W3175110217 hasConceptScore W3175110217C1862650 @default.
• W3175110217 hasConceptScore W3175110217C187960798 @default.
• W3175110217 hasConceptScore W3175110217C2777106319 @default.
• W3175110217 hasConceptScore W3175110217C2777683783 @default.
• W3175110217 hasConceptScore W3175110217C2778186239 @default.
• W3175110217 hasConceptScore W3175110217C2778541695 @default.
• W3175110217 hasConceptScore W3175110217C2780966972 @default.
• W3175110217 hasConceptScore W3175110217C2910587157 @default.
• W3175110217 hasConceptScore W3175110217C33923547 @default.
• W3175110217 hasConceptScore W3175110217C512399662 @default.
• W3175110217 hasConceptScore W3175110217C535046627 @default.
• W3175110217 hasConceptScore W3175110217C71924100 @default.
• W3175110217 hasConceptScore W3175110217C95190672 @default.
• W3175110217 hasLocation W31751102171 @default.
• W3175110217 hasOpenAccess W3175110217 @default.
• W3175110217 hasPrimaryLocation W31751102171 @default.
• W3175110217 hasRelatedWork W2803840290 @default.
• W3175110217 hasRelatedWork W2805440854 @default.
• W3175110217 hasRelatedWork W2805955440 @default.
• W3175110217 hasRelatedWork W2808748844 @default.
• W3175110217 hasRelatedWork W2808993196 @default.
• W3175110217 hasRelatedWork W2811121788 @default.
• W3175110217 hasRelatedWork W2887666462 @default.
• W3175110217 hasRelatedWork W2893615962 @default.
• W3175110217 hasRelatedWork W2898179314 @default.
• W3175110217 hasRelatedWork W2913295245 @default.
• W3175110217 hasRelatedWork W2953644271 @default.
• W3175110217 hasRelatedWork W2982561889 @default.
• W3175110217 hasRelatedWork W3000418578 @default.
• W3175110217 hasRelatedWork W3034777552 @default.
• W3175110217 hasRelatedWork W3047736609 @default.
• W3175110217 hasRelatedWork W3121083325 @default.
• W3175110217 hasRelatedWork W3191369108 @default.
• W3175110217 hasRelatedWork W3196376434 @default.
• W3175110217 hasRelatedWork W3210087989 @default.
• W3175110217 hasRelatedWork W3212362547 @default.
• W3175110217 hasVolume "92" @default.
• W3175110217 isParatext "false" @default.
• W3175110217 isRetracted "false" @default.
• W3175110217 magId "3175110217" @default.
• W3175110217 workType "article" @default.